These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 12198632)

  • 21. Luteinizing hormone-releasing hormone agonists in prostate cancer. Elimination of flare reaction by pretreatment with cyproterone acetate and low-dose diethylstilbestrol.
    Bruchovsky N; Goldenberg SL; Akakura K; Rennie PS
    Cancer; 1993 Sep; 72(5):1685-91. PubMed ID: 7688656
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In regard to Padula et al., normalization of serum testosterone levels in patients treated with neoadjuvant hormonal therapy and three-dimensional conformal radiotherapy for prostate cancer. IJROBP 2002;52: 439-443.
    Dearnaley DP; Norman AR; Shahidi M
    Int J Radiat Oncol Biol Phys; 2002 Nov; 54(3):981; author reply 981. PubMed ID: 12377353
    [No Abstract]   [Full Text] [Related]  

  • 23. Leuprorelin, triptorelin: new indications. Locally advanced prostate cancer: minimally assessed me-toos.
    Prescrire Int; 2007 Dec; 16(92):243. PubMed ID: 18092407
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
    Kobayashi T; Nishizawa K; Mitsumori K
    Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancer.
    Appu S; Lawrentschuk N; Grills RJ; Neerhut G
    J Urol; 2005 Jul; 174(1):140-2. PubMed ID: 15947599
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist.
    Crawford ED; Tombal B; Keane T; Boccardo F; Miller K; Shore N; Moul JW; Damber JE; Collette L; Persson BE
    Scand J Urol; 2018; 52(5-6):349-357. PubMed ID: 30624128
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer.
    Clinton TN; Woldu SL; Raj GV
    Expert Opin Pharmacother; 2017 Jun; 18(8):825-832. PubMed ID: 28480768
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Hormonal therapy for prostatic cancer--state of the art].
    Miyakita H
    Nihon Rinsho; 2005 Feb; 63(2):305-8. PubMed ID: 15714983
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of medical castration on CYP3A4 enzyme activity using the erythromycin breath test.
    Hutson PR; Oettel K; Douglas J; Ritter M; Messing E; Staab MJ; Alberti D; Horvath D; Wilding G
    Cancer Chemother Pharmacol; 2008 Aug; 62(3):373-7. PubMed ID: 17922273
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk of disease flare with LHRH agonist therapy in men with prostate cancer: myth or fact?
    Vis AN; van der Sluis TM; Al-Itejawi HHM; van Moorselaar RJA; Meuleman EJH
    Urol Oncol; 2015 Jan; 33(1):7-15. PubMed ID: 25159013
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancer.
    Kirby RS; Fitzpatrick JM; Clarke N
    BJU Int; 2009 Dec; 104(11):1580-4. PubMed ID: 20053189
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Testosterone measurement in patients with prostate cancer.
    Schulman CC; Irani J; Morote J; Schalken JA; Montorsi F; Chlosta PL; Heidenreich A
    Eur Urol; 2010 Jul; 58(1):65-74. PubMed ID: 20434831
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hormonal treatment of prostate cancer.
    Garnick MB
    N Engl J Med; 1999 Mar; 340(10):812-3. PubMed ID: 10075531
    [No Abstract]   [Full Text] [Related]  

  • 34. [Cost-utility analysis of androgen ablation therapy in metastatic prostate cancer].
    Fujikawa K; Awakura Y; Okabe T; Watanabe R; Nishimura S
    Nihon Hinyokika Gakkai Zasshi; 2003 May; 94(4):503-11; discussion 511-2. PubMed ID: 12795165
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Does Exist a Differential Impact of Degarelix
    Sciarra A; Busetto GM; Salciccia S; Del Giudice F; Maggi M; Crocetto F; Ferro M; De Berardinis E; Scarpa RM; Porpiglia F; Carmignani L; Damiano R; Artibani W; Carrieri G
    Front Endocrinol (Lausanne); 2021; 12():695170. PubMed ID: 34194398
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An open-label study of abarelix in men with symptomatic prostate cancer at risk of treatment with LHRH agonists.
    Koch M; Steidle C; Brosman S; Centeno A; Gaylis F; Campion M; Garnick MB;
    Urology; 2003 Nov; 62(5):877-82. PubMed ID: 14624912
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Are all gonadotrophin-releasing hormone agonists equivalent for the treatment of prostate cancer? A systematic review.
    Bolton EM; Lynch T
    BJU Int; 2018 Sep; 122(3):371-383. PubMed ID: 29438592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Response to degarelix after resistance to luteinizing hormone-releasing hormone agonist therapy for metastatic prostate cancer.
    Raddin RS; Walko CM; Whang YE
    Anticancer Drugs; 2011 Mar; 22(3):299-302. PubMed ID: 21360851
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Total androgen blockade].
    Namiki M; Mizokami A
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():193-8. PubMed ID: 12599570
    [No Abstract]   [Full Text] [Related]  

  • 40. Management of advanced prostate cancer: can we improve on androgen deprivation therapy?
    Anderson J; Abrahamsson PA; Crawford D; Miller K; Tombal B
    BJU Int; 2008 Jun; 101(12):1497-501. PubMed ID: 18336613
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.